超声引导微波消融结合门静脉灌注对肝癌门静脉癌栓的预防价值  

Ultrasound-guided microwave ablation combined with portal vein perfusion chemotherapy for prevention of portal vein tumor thrombus in hepatocellular carcinoma

作　　者：孙厚坦[1] 杨峰[1] 赵威武 陈朝旻[1] 滕红 徐晓燕[1] 张明立 

机构地区：[1]兰州军区兰州总医院安宁分院影像特诊科,甘肃兰州730070 [2]兰州介入超声诊疗技术研究中心

出　　处：《西北国防医学杂志》2013年第5期421-423,共3页Medical Journal of National Defending Forces in Northwest China

摘　　要：目的:探讨超声引导经皮微波消融结合门静脉灌注化疗对肝癌门静脉癌栓的预防作用。方法:78例未形成门静脉癌栓的原发性肝癌患者,采用微波消融结合门静脉灌注化疗治疗。治疗后定期对所有患者进行肝癌血清学指标甲胎蛋白(AFP)检测,超声或CT检查肿瘤新生结节及门静脉癌栓形成情况,并随访患者复发率及生存率。结果:78例患者0.5、1、2、3年复发率分别为5.12%、11.53%、20.51%、35.90%,生存率分别为97.43%、94.87%、75.64%、39.74%,3年间无一例门静脉癌栓发生。结论:超声引导经皮微波消融联合门静脉灌注化疗治疗肝癌疗效明显并可延长患者生存期,对门静脉癌栓的形成有一定的预防作用。Objective： To investigate the effect of percutaneous microwave ablation and portal vein perfusion chemotherapy under ultrasound guidance on the prevention of portal vein tumor thrombus （PVTr） in hepatocellular carcinoma （ HCC ）. Methods： A total of 78 cases of hepatocellular carcinoma without pVrlT were treated by micro- wave ablation and portal vein perfusion chemotherapy. The serum fetoprotein （AFP） was determined after therapy, the new tumor nodules and portal vein tumor thrombus were identified by ultrasound and CT scanning, and the recurrence status and survival time were recorded for all patients. Results： The 0.5 -, 1 -, 2 - , and 3 - year recurrence rates were 5. 12%, 11. 53%, 20. 51% and 35. 90% respectively, and the survival rates were 97.43%, 94.87%, 75.64% and 39.74% respectively. No PV3T was found during the 3 - year follow - up peri- od. Conclusion：Percutaneous microwave ablation combined with portal vein perfusion chemotherapy under ultra- sound guidance could improve the therapeutic efficacy and increase the survival rate, which may prevent the tumor thrombosis in portal vein.

关 键 词：肝癌 超声介入 微波消融 门静脉癌栓 局部灌注 

分 类 号：R735.7[医药卫生—肿瘤]